Wouters, Olivier J.

Number of items: 65.

Care Policy and Evaluation Centre

Wouters, Olivier J., Shadlen, Kenneth C, Salcher-konrad, Maximilian, Pollard, Andrew J, Larson, Heidi J, Teerawattananon, Yot, Jit, Mark (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet, 397(10278), 1023 - 1034. https://doi.org/10.1016/S0140-6736(21)00306-8

European Institute

Wouters, Olivier J., Kanavos, Panos (2017). A comparison of generic drug prices in seven European countries: a methodological analysis. BMC Health Services Research, 17(242), 1-7. https://doi.org/10.1186/s12913-017-2184-5

Health Policy

Papanicolas, Irene, Wouters, Olivier J., Sawaya, Tania, Han, Jihye, Wei, Jinru, Naci, Huseyin (2026). Review times for new drugs and submission delays among the FDA and 4 international regulators, 2014–22. Health Affairs, 45(2), 184-192. https://doi.org/10.1377/hlthaff.2025.00595

Singh, Yashaswini, Reddy, Megha, Mehta, Neil K, Rooke-Ley, Hayden, Wouters, Olivier J., Fuse Brown, Erin C. (5 December 2025) Unpacking private equity investments in drug industry third-party entities. Health Affairs Forefront. https://doi.org/10.1377/forefront.20251203.568413

Cherla, Avi, Wagner, Anita K., Wouters, Olivier J., Woloshin, Steven, Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2025). Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines. JAMA, 334(16), 1480 - 1482. https://doi.org/10.1001/jama.2025.13917

Wouters, Olivier J., Denolle, Cyprien, Wei, Jinru, Papanicolas, Irene (2025). Prices and affordability of essential medicines in 72 low-, middle-, and high-income markets. JAMA Health Forum, 6(8). https://doi.org/10.1001/jamahealthforum.2025.2043

Cherla, Avi, Woloshin, Steven, Wagner, Anita K., Wouters, Olivier J., Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2025). New cancer drug approvals: less than half of important clinical trial uncertainties reported by the FDA to clinicians, 2019–22. Health Affairs, 44(7), 830 - 838. https://doi.org/10.1377/hlthaff.2024.01134

Chan, Mei Xuan Jessalyn, Wouters, Olivier J., Chan, Hui Yun, Terblanche, Petro, Premsri, Nakorn, Kim, Jerome H., Lim, John C.W., Tan-Koi, Wei Chuen, Jit, Mark (2025). Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective. Vaccine, 53, https://doi.org/10.1016/j.vaccine.2025.127107

Wouters, Olivier J., Sullivan, Sean D., Cousin, Emma M., Gabriel, Nico, Papanicolas, Irene, Hernandez, Inmaculada (2024). Drug prices negotiated by medicare vs US net prices and prices in other countries. JAMA, 333(1), 85-87. https://doi.org/10.1001/jama.2024.22582

Wouters, Olivier J., Vogel, Matthew, Feldman, William B., Beall, Reed F., Kesselheim, Aaron S., Tu, S. Sean (2024). Differential legal protections for biologics vs. small-molecule drugs in the US. JAMA, 332(24), 2101 - 2108. https://doi.org/10.1001/jama.2024.16911

Sullivan, Sean D., Wouters, Olivier J., Cousin, Emma M., Kirihennedige, Ayuri S., Hernandez, Inmaculada (2024). Integrating price benchmarks and comparative clinical effectiveness to inform the medicare drug price negotiation program. Value in Health, 27(10), 1348 - 1357. https://doi.org/10.1016/j.jval.2024.08.001

Wouters, Olivier J., Kesselheim, Aaron S., Kuha, Jouni, Luyten, Jeroen (2024). Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014: a retrospective study. Value in Health, 27(10), 1373 - 1381. https://doi.org/10.1016/j.jval.2024.06.015

Wouters, Olivier J., Kuha, Jouni (2024). Low- and middle-income countries experienced delays accessing new essential medicines, 1982–2024. Health Affairs, 43(10), 1410 - 1419. https://doi.org/10.1377/hlthaff.2024.00089

Hernandez, Inmaculada, Wouters, Olivier J., Cousin, Emma M., Kirihennedige, Ayuri S., Sullivan, Sean D. (3 September 2024) Interpreting the first round of maximum fair prices negotiated by Medicare for drugs. Health Affairs Forefront. https://doi.org/10.1377/forefront.20240830.863408

Hernandez, Inmaculada, Cousin, Emma M., Wouters, Olivier J., Gabriel, Nico, Cameron, Teresa, Sullivan, Sean D. (2024). Price benchmarks of drugs selected for medicare price negotiation and their therapeutic alternatives. Journal of Managed Care & Specialty Pharmacy, 30(8), 762 - 772. https://doi.org/10.18553/jmcp.2024.24153

Wouters, Olivier J., Naci, Huseyin, Papanicolas, Irene (2024). Health Technology Assessment in the US—a word of caution—reply. JAMA Internal Medicine, 184(7), 851 - 851. https://doi.org/10.1001/jamainternmed.2024.1461

Wouters, Olivier J., Kesselheim, Aaron S. (2024). Quantifying research and development expenditures in the drug industry. JAMA network open, 7(6). https://doi.org/10.1001/jamanetworkopen.2024.15407

Wouters, Olivier J. (2024). Lobbying in US health care: lessons from the field of oncology. JNCCN, 22(4), 275 - 276. https://doi.org/10.6004/jnccn.2024.7034

Wouters, Olivier J., Naci, Huseyin, Papanicolas, Irene (2024). Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies. Journal of American Medical Association: Internal Medicine, 184(3), 328 - 330. https://doi.org/10.1001/jamainternmed.2023.7726

Hernandez, Inmaculada, Cousin, Emma, Wouters, Olivier J., Gabriel, Nico, Cameron, Teresa, Sullivan, Sean D. (2024). Medicare drug price negotiation: the complexities of selecting therapeutic alternatives for estimating comparative effectiveness. Journal of Managed Care & Specialty Pharmacy, 30(3), 218 - 225. https://doi.org/10.18553/jmcp.2023.23277

Vokinger, Kerstin N., Perényi, Gellért, Wouters, Olivier J. (2023). Investments in research and development for supplemental drug indications: implications for drug price negotiations. JAMA Health Forum, 4(9), E232798. https://doi.org/10.1001/jamahealthforum.2023.2798

Wouters, Olivier J., Forman, Rebecca, Anderson, Michael, Mossialos, Elias, McKee, Martin (2023). The launch of the EU Health Emergency Preparedness and Response Authority (HERA) improving global pandemic preparedness? Health Policy, 133, https://doi.org/10.1016/j.healthpol.2023.104844

van Kessel, Robin, Forman, Rebecca, Milstein, Ricarda, Mastylak, Alicja, Czabanowska, Katarzyna, Czypionka, Thomas, Durand-Zaleski, Isabelle, Hirche, Anja, Krysinska-Pisarek, Magdalena & Roberts, Bjelle et al (2023). Divergent COVID-19 vaccine policies: policy mapping of ten European countries. Vaccine, 41(17), 2804 - 2810. https://doi.org/10.1016/j.vaccine.2023.03.036

Anderson, Michael, Wouters, Olivier J., Mossialos, Elias (2023). Transferable exclusivity extensions to stimulate antibiotic research and development what is at stake? The Lancet Microbe, 4(3), e127-e128. https://doi.org/10.1016/S2666-5247(22)00336-6

Angelis, Aris, Polyakov, Roman, Wouters, Olivier J., Torreele, Els, McKee, Martin (2023). High drug prices are not justified by industry’s spending on research and development. BMJ, 380(8371). https://doi.org/10.1136/bmj-2022-071710

Feldman, William B., Tu, S. Sean, Alhiary, Rasha, Kesselheim, Aaron S., Wouters, Olivier J. (2023). Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. JAMA, 329(1), 87 - 89. https://doi.org/10.1001/jama.2022.19691

Wouters, Olivier J., Feldman, William B., Tu, S. Sean (2022). Product hopping in the drug industry — lessons from Albuterol. New England Journal of Medicine, 387(13), 1153 - 1156. https://doi.org/10.1056/NEJMp2208613

Wouters, Olivier J., Berenbrok, Lucas A., He, Meiqi, Li, Yihan, Hernandez, Inmaculada (2022). Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018. JAMA network open, 5(9). https://doi.org/10.1001/jamanetworkopen.2022.18623

Wouters, Olivier J., McKee, Martin, Luyten, Jeroen (2022). Errors in source data for study of drug development costs. JAMA, 328(11), p. 1110. https://doi.org/10.1001/jama.2022.14317

McKee, Martin, Wouters, Olivier J. (2022). The challenges of regulating artificial intelligence in healthcare comment on “Clinical decision support and new regulatory frameworks for medical devices: are we ready for it? - a viewpoint paper”. International Journal of Health Policy and Management, 12(1), 1-4. https://doi.org/10.34172/ijhpm.2022.7261

Wenham, Clare, Wouters, Olivier J., Jones, Catherine M., Juma, Pamela A., Mijumbi-Deve, Rhona M., Sobngwi-Tambekou, Joëlle L., Parkhurst, Justin (2021). Measuring health science research and development in Africa: mapping the available data. Health Research Policy and Systems, 19(1). https://doi.org/10.1186/s12961-021-00778-y

Jit, Mark, Ananthakrishnan, Aparna, McKee, Martin, Wouters, Olivier J., Beutels, Philippe, Teerawattananon, Yot (2021). Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic. The Lancet Regional Health - Europe, 9, https://doi.org/10.1016/j.lanepe.2021.100221

Wouters, Olivier J., Shadlen, Kenneth C, Salcher-konrad, Maximilian, Pollard, Andrew J, Larson, Heidi J, Teerawattananon, Yot, Jit, Mark (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet, 397(10278), 1023 - 1034. https://doi.org/10.1016/S0140-6736(21)00306-8

Wouters, Olivier J. (24 February 2021) Vaccine nationalism risks prolonging the global pandemic. LSE COVID-19 Blog.

Shi, Wunan, Wouters, Olivier J., Liu, Gordon, Mossialos, Elias, Yang, Xiuyun (2020). Association between provincial income levels and drug prices in China over the period 2010–2017. Social Science & Medicine, 263, https://doi.org/10.1016/j.socscimed.2020.113247

Luyten, Jeroen, McKee, Martin, Wouters, Olivier J. (2020). Wat kost onderzoek en ontwikkeling van een medicijn? Een oproep tot meer transparantie. Nederlands Tijdschrift voor Geneeskunde, 164(34).

Wouters, Olivier J., McKee, Martin, Luyten, Jeroen (2020). Research and development costs of new drugs: in reply. JAMA, 324(5), p. 518. https://doi.org/10.1001/jama.2020.8651

van Schalkwyk, May C.I., Jarman, Holly, Hervey, Tamara, Wouters, Olivier J., Barlow, Pepita, McKee, Martin (2020). Risks to health and the NHS in the post-Brexit era. BMJ (Clinical research ed.), 369, https://doi.org/10.1136/bmj.m2307

Wouters, Olivier J. (2020). Lobbying expenditures and campaign contributions by the pharmaceutical and health-product industry in the United States, 1999- 2018. Journal of American Medical Association: Internal Medicine, 180(5), 688 - 697. https://doi.org/10.1001/jamainternmed.2020.0146

Wouters, Olivier J., Hervey, Tamara, McKee, Martin (2020). Brexit and the European Medicines Agency—what next for the Agency and UK drug regulators? JAMA Health Forum, 1(2), E200135. https://doi.org/10.1001/jamahealthforum.2020.0135

Wouters, Olivier J., Sandberg, Dale M., Pillay, Anban, Kanavos, Panos (2018). The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Social Science & Medicine, https://doi.org/10.1016/j.socscimed.2018.11.029

Wouters, Olivier J., Kanavos, Panos, McKee, Martin (2017). Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. The Milbank Quarterly, 95(3), 554 - 601. https://doi.org/10.1111/1468-0009.12279

Wouters, Olivier J., Kanavos, Panos (2017). A comparison of generic drug prices in seven European countries: a methodological analysis. BMC Health Services Research, 17(242), 1-7. https://doi.org/10.1186/s12913-017-2184-5

Laviolette, Luc, Gopalan, Sudararajan, Elder, Leslie, Wouters, Olivier J. (2016). Incentivizing nutrition: how to apply incentive mechanisms to accelerate improved nutrition outcomes: a practitioner’s compendium. World Bank.

Laviolette, Luc, Gopalan, Sudararajan, Elder, Leslie, Wouters, Olivier J. (2016). Incentivizing nutrition: incentive mechanisms to accelerate improved nutrition outcomes. World Bank.

Wouters, Olivier J., O'Donoghue, Donal J., Ritchie, James, Kanavos, Panos, Narva, Andrew S. (2015). Early chronic kidney disease: diagnosis, management and models of care. Nature Reviews Nephrology, 11(8), 491-502. https://doi.org/10.1038/nrneph.2015.85

Wouters, Olivier J., Kanavos, Panos (2015). Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Bulletin of the World Health Organization, 93(9), 606-613. https://doi.org/10.2471/BLT.14.148742

International Development

Wouters, Olivier J., Shadlen, Kenneth C, Salcher-konrad, Maximilian, Pollard, Andrew J, Larson, Heidi J, Teerawattananon, Yot, Jit, Mark (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet, 397(10278), 1023 - 1034. https://doi.org/10.1016/S0140-6736(21)00306-8

LSE

Teng, Theodore W., Tu, S. Sean, Mooney, Helen, Bendicksen, Liam, Gabriele, Sarah M.E., Wouters, Olivier J., Feldman, William B. (2026). Tertiary patents on drugs approved by the FDA. JAMA Health Forum, 7(1), e255909. https://doi.org/10.1001/jamahealthforum.2025.5909

Vogel, Matthew, Feldman, William B., Cowan, Zander, Rome, Benjamin N., Chandra, Amitabh, Kesselheim, Aaron S., Wouters, Olivier J. (2025). Revenue differences between top-selling small-molecule drugs and biologics in medicare. JAMA Health Forum, 6(10). https://doi.org/10.1001/jamahealthforum.2025.4720

Vokinger, Kerstin N., Li, Guanqiao, Wouters, Olivier J. (2025). The rise of drug innovation in China - implications for patient access in the United States and globally. New England Journal of Medicine, 393(9), 839-841. https://doi.org/10.1056/NEJMp2505821

Fuse Brown, Erin C., Wouters, Olivier J., Mehrotra, Ateev (2025). Partnerships between pharmaceutical and telehealth companies-increasing access or driving inappropriate prescribing? New England Journal of Medicine, 392(12), 1148-1151. https://doi.org/10.1056/NEJMp2500379

Kanavos, Panos, Wouters, Olivier J. (2017). Health care after the Great Recession: financing options for sustainable and high-quality health systems. Global Policy, 8(S2), 5-6. https://doi.org/10.1111/1758-5899.12389

Cylus, Jonathan, Wouters, Olivier J., Kanavos, Panos (2015). Understanding the role of governance in the pharmaceutical sector: from laboratory to patient. In Greer, Scott, Wismar, Matthias, Figueras, Josep (Eds.), Strengthening Health System Governance: Better Policies, Stronger Performance (pp. 175-187). Open University.

LSE Health

Wouters, Olivier J., Forman, Rebecca, Anderson, Michael, Mossialos, Elias, McKee, Martin (2023). The launch of the EU Health Emergency Preparedness and Response Authority (HERA) improving global pandemic preparedness? Health Policy, 133, https://doi.org/10.1016/j.healthpol.2023.104844

van Kessel, Robin, Forman, Rebecca, Milstein, Ricarda, Mastylak, Alicja, Czabanowska, Katarzyna, Czypionka, Thomas, Durand-Zaleski, Isabelle, Hirche, Anja, Krysinska-Pisarek, Magdalena & Roberts, Bjelle et al (2023). Divergent COVID-19 vaccine policies: policy mapping of ten European countries. Vaccine, 41(17), 2804 - 2810. https://doi.org/10.1016/j.vaccine.2023.03.036

Wouters, Olivier J., Kanavos, Panos, McKee, Martin (2017). Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. The Milbank Quarterly, 95(3), 554 - 601. https://doi.org/10.1111/1468-0009.12279

Naci, Huseyin, Wouters, Olivier J., Gupta, Radhika, Ioannidis, John P. A. (2017). Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. The Milbank Quarterly, 95(2), 261 - 290. https://doi.org/10.1111/1468-0009.12261

Wouters, Olivier J., McKee, Martin (2017). Private financing of health care in times of economic crisis: a review of the evidence. Global Policy, 8(S2), 23-29. https://doi.org/10.1111/1758-5899.12211

Wouters, Olivier J., Cylus, Jonathan, Yang, Wei, Thomson, Sarah, McKee, Martin (2016). Medical savings accounts: assessing their impact on efficiency, equity, and financial protection in health care. Health Economics, Policy and Law, 11(3), 321-335. https://doi.org/10.1017/S1744133116000025

Wouters, Olivier J., Naci, Huseyin, Samani, Nilesh J (2015). QALYs in cost-effectiveness analysis: an overview for cardiologists. Heart, 10(23), 1868-1873. https://doi.org/10.1136/heartjnl-2015-308255

Wouters, Olivier J., Kanavos, Panos (2015). Primary health care should play bigger role in treating chronic kidney disease.

Naci, Huseyin, Lehman, Richard, Wouters, Olivier J., Goldacre, Ben, Yudkin, John S (2015). Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ, 351(h5260). https://doi.org/10.1136/bmj.h5260

Chambers, James D., Naci, Huseyin, Wouters, Olivier J., Pyo, Junhee, Gunjal, Shalak, Kennedy, Ian R., Hoey, Mark G., Winn, Aaron, Neumann, Peter J. (2015). An assessment of the methodological quality of published network meta-analyses: a systematic review. PLOS ONE, 10(4). https://doi.org/10.1371/journal.pone.0121715

Kanavos, Panos, Wouters, Olivier J. (2014). Pharmaceutical policies in Cyprus: a review of the current system and future options. World Health Organization.

Kanavos, Panos, Wouters, Olivier J. (2014-02-27 - 2014-02-28) Competition issues in the distribution of pharmaceuticals [Paper]. OECD Global Forum on Competition, Paris, France, FRA.

Methodology

Panteli, Dimitra, Arickx, Francis, Cleemput, Irina, Dedet, Guillaume, Eckhardt, Helene, Fogarty, Emer, Gerkens, Sophie, Henschke, Cornelia, Hislop, Jennifer & Jommi, Claudio et al (2016). Pharmaceutical regulation in 15 European countries: review. Health Systems in Transition, 18(5), 1-118.

Social Policy

Wouters, Olivier (2018). Essays on prices, volumes, and policies in generic drug markets in high- and middle-income countries [Doctoral thesis]. London School of Economics and Political Science. https://doi.org/10.21953/lse.ppv5qzbr6y8s

Wouters, Olivier J., Kanavos, Panos (2017). A comparison of generic drug prices in seven European countries: a methodological analysis. BMC Health Services Research, 17(242), 1-7. https://doi.org/10.1186/s12913-017-2184-5

Kanavos, Panos, Wouters, Olivier J. (2014). Pharmaceutical parallel trade: legal, policy, and economic issues. In Culyer, Anthony J. (Ed.), Encyclopedia of health economics (pp. 20-28). Elsevier (Firm).

Wouters, Olivier J., Downs, Philip W., Zoerhoff, Kathryn L., Crowley, Kathryn R., Frawley, Hannah, Einberg, Jennifer, Chu, Brian K., Brady, Molly A., Oscar, Roland & Jeudi, Mireille et al (2014). Resource planning for Neglected Tropical Disease (NTD) Control Programs: feasibility study of the Tool for Integrated Planning and Costing (TIPAC). PLoS Neglected Tropical Diseases, 8(2), e2619. https://doi.org/10.1371/journal.pntd.0002619

Kanavos, Panos, Wouters, Olivier J. (2014-02-27 - 2014-02-28) Concurrence dans la distribution de produits pharmaceutiques [Paper]. OECD Forum Mondial sur la Concurrence, Paris, France, FRA.

Kanavos, Panos, Wouters, Olivier J. (2014-02-27 - 2014-02-28) Competition issues in the distribution of pharmaceuticals [Paper]. OECD Global Forum on Competition, Paris, France, FRA.

Statistics

Wouters, Olivier J., Kesselheim, Aaron S., Kuha, Jouni, Luyten, Jeroen (2024). Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014: a retrospective study. Value in Health, 27(10), 1373 - 1381. https://doi.org/10.1016/j.jval.2024.06.015

Wouters, Olivier J., Kuha, Jouni (2024). Low- and middle-income countries experienced delays accessing new essential medicines, 1982–2024. Health Affairs, 43(10), 1410 - 1419. https://doi.org/10.1377/hlthaff.2024.00089